ALK and non-small cell lung carcinoma: The combination of vincristine with ALK‐TKIs, crizotinib or ceritinib, elicited antiproliferative activities and inhibition of signalling pathways in Variant 1, but not in Variant 3‐bearing EML4‐ALK+ NSCLC cells [71].